Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Study Summary

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Conditions

Locally Advanced Solid Tumor

Interventions / Drugs

TNG908

View on ClinicalTrials.gov ↗

Sponsor

TNGX

Tango Therapeutics, Inc.

Biotech / Pharma

D40/100

Study Details

Enrollment192 participants

Primary Completion—

Lead SponsorTango Therapeutics, Inc.

Data Retrieved2026-04-11 04:29:38.262408+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.